Compare Heron Therapeutics Inc (HRTX) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs MobilEye Global Inc — how do they compare? Heron Therapeutics Inc trades at $0.38 (market cap $68.01M), while MobilEye Global Inc trades at $7.2 (market cap $6.00B). The key difference: MobilEye Global Inc is far larger — about 88.2× Heron Therapeutics Inc's market cap, and MobilEye Global Inc is more actively traded (7,007,849 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and MobilEye Global Inc for 15 Days on average.
| HRTX | MBLY | |
|---|---|---|
Market Cap | $68.01M | $6.00B |
Volume | 1,891,941 | 7,007,849 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $15.42 |
52-Week Low | $0.27 | $6.56 |
Typical Hold Time | 35 Days | 15 Days |
Enterprise Value | $174.75M | $4.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Mobileye Global (MBLY) trades at $7.14, down 0.14% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $2.0B in 2026 but faces significant profitability challenges with a -201.49% net income margin. Analyst consensus is mixed with 57.7% buy ratings but a bearish technical outlook from indicators.
The stock presents a high-risk opportunity with substantial upside to the $10.83 consensus target but requires careful monitoring of profitability improvements. Key risks include persistent losses, competitive pressures in autonomous driving, and execution challenges in robotaxi expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
